论文部分内容阅读
目的评估索拉非尼治疗晚期肾癌的疗效和安全性。方法回顾性分析应用索拉非尼治疗的37例晚期肾癌患者的临床资料,根据转移部位分为单发转移组(24例)与多发转移组(13例);根据斯隆-凯特琳癌症中心(MSKCC)危险度预测模型又分为低危组(15例)、中危组(9例)、高危组(13例)。结果 37例中,部分缓解3例(8.1%),疾病稳定28例(75.7%),疾病进展6例(16.2%),疾病控制率83.8%,中位生存时间21个月。单发转移组的3年生存率优于多发转移组(P<0.05);MSKCC低危组的2、3年生存率均优于MSKCC中/高危组(P<0.05)。不良反应主要为Ⅰ-Ⅱ级手足皮肤反应、腹泻。结论索拉非尼治疗晚期肾癌近期和远期疗效良好,患者耐受性较好。
Objective To evaluate the efficacy and safety of sorafenib in the treatment of advanced renal cell carcinoma. Methods The clinical data of 37 patients with advanced renal cell carcinoma treated with sorafenib were retrospectively analyzed. According to the metastatic sites, they were divided into single metastasis group (24 cases) and multiple metastasis group (13 cases). According to Sloan-Kettering Cancer Center (MSKCC) risk prediction model is divided into low-risk group (15 cases), moderate-risk group (9 cases) and high-risk group (13 cases). Results Among the 37 cases, partial relief was achieved in 3 cases (8.1%), stable disease in 28 cases (75.7%), disease progression in 6 cases (16.2%), disease control rate in 83.8% and median survival time in 21 months. The 3-year survival rate of single-metastasis group was better than that of multiple metastasis group (P <0.05). The 2-year and 3-year survival rates of MSKCC low-risk group were better than that of MSKCC middle-high risk group (P <0.05). Adverse reactions are mainly Ⅰ-Ⅱ hand-foot skin reaction, diarrhea. Conclusion Sorafenib in the treatment of advanced renal cell carcinoma has good curative effect in the short and long term, and the patients are well tolerated.